Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

ovarian cancer drug market will more than triple over the next decade, increasing from $460 million in 2011 to $1.4 billion in 2021 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

http://www.fiercebiotech.com/biotech/ovarian-cancer-drug-market-will-more-than-triple-over-next-decade-increasing-from-460

Once Kevetrin is approved by the FDA then it will also become elligible for the various Moonshot 20/20 Cancer consortiums, like the one directed at pediatric cancers run by Dr.Shiong, that will only look at FDA approved cancer drugs for clinical trials aimed at finding effective combo treatments.

As Kevetrin's ODD indicates, the OC market is small, but the real value here is that it represent the speediest path to market. The way I see it, the quicker Kevetrin can hit the market, the quicker these consortiums can help CTIX identify what I believe will many dozens of "combos" for which Kevetrin could play an effective role.